论文部分内容阅读
2016年是我国“十三五”开局之年。随着宏观经济步入L型轨迹,医药行业增速亦相对放缓。近年来国家药物政策密集发布,监管力度不断加大,使产业界面临更多机遇和挑战。然而供给侧结构性改革、行业提质增速等宏观调控已催生经济增长新引擎,“蓄”字当头,“势”不可挡!与此同时,医药健康产业新生态展现蓬勃生机:新技术与传统健康产业碰撞交融,大数据拥抱健康产品和医
2016 is China’s “Thirteen Five” first year. As the macro-economy entered the L-shaped trajectory, the growth rate of the pharmaceutical industry also slowed down relatively. In recent years, the national drug policy has been intensively released and regulatory efforts have been steadily intensified, giving the industry more opportunities and challenges. However, macroeconomic regulation and control such as supply-side structural reforms and industrial upgrading have given birth to new engines of economic growth. At the same time, the new ecology of the pharmaceutical and health industry shows its vitality : New technologies collide with traditional health industries and big data embraces health products and medicine